MEMiquel Ensenyat-Mendez

Miquel Ensenyat-Mendez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Miquel Ensenyat-Mendez has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Primary Tumor Epigenetic and Transcriptomic Alterations Associated with Nodal Burden and Metastatic Risk in ER+/HER2− Breast Cancer

    by Sandra Iñiguez-Muñoz, Andrés F. Bedoya-López, Miquel Ensenyat-Mendez, Pere Llinàs-Arias, Sookyung Ahn, Rachel E. Factor, Diego M. Marzese, Maggie L. DiNome

    De-escalation of axillary surgery has resulted in the loss of pathologic nodal information, yet the extent of lymph node involvement remains an important determinant of treatment decisions in estrogen receptor-positive (ER+)/HER2− disease. We examined whether primary tumors differed molecularly according to the extent of this regional dissemination. Genome-wide DNA methylation profiling of primary ER+/HER2− tumors from 47 patients with pN1 (n = 29) vs. >pN1 (n = 18) disease showed differences concentrated at promoters of developmental and cell-adhesion genes. By integrating methylomes with transcriptomes from the TCGA-BRCA cohort (n = 148) and clinical outcomes from KM Plotter (RFS, n = 1154; OS, n = 442; DMFS, n = 423), we identified four genes (ARL10, RIC3, CXCL14, KCNH2) showing concordant molecular and clinical associations, from which we derived the Lymph-node Involvement Outcome Numerator (LION) score. Lower LION scores were observed in metastatic lesions from the AURORA US cohort (n = 45). In SCAN-B (n = 3969), lower scores were associated with shorter distant recurrence-free intervals (HR = 0.38; 95% CI 0.23–0.62); this association persisted after adjustment for age, nodal and tumor category but was lost after adjustment for histological grade (HR = 0.83; 95% CI 0.48–1.44), indicating that the score and grade capture overlapping biology. These findings suggest that primary tumors already display coordinated epigenetic and transcriptional alterations associated with the extent of metastatic dissemination.

  • Open Access

    Tumor-Intrinsic Epigenetic Programs Associated with Nodal Burden and Metastatic Risk in ER+/HER2- Breast Cancer

    by Sandra Iñiguez-Muñoz, Andrés F. Bedoya-López, Miquel Ensenyat-Mendez, Pere Llinàs-Arias, Sookyung Ahn, Rachel E. Factor, Diego M. Marzese, Maggie L. DiNome

    De-escalation of axillary surgery in breast cancer (BC) reduces surgical morbidity but limits pathological assessment of nodal burden, a key determinant of prognosis and adjuvant therapy in estrogen receptor-positive (ER+)/HER2- BC. Tumor-intrinsic biomarkers that reflect the extent of lymph node disease may help bridge this gap. We performed genome-wide DNA methylation profiling of primary tumors from patients with ER+/HER2- BC stratified by pathological nodal stage (1-3 positive nodes, pN1; 4 or more positive nodes, >pN1). Findings were validated across multiple independent cohorts (TCGA-BRCA, SCAN-B, AURORA US), integrating molecular and clinical data. Forty-seven tumors passed EPIC quality control (pN1: n=29; >pN1: n=18). Tumors with >pN1 disease showed epigenetic reprogramming, including promoter hypermethylation and suppression of genes in pathways related to development and cell adhesion. Across datasets, five genes (TTC23, ARL10, RIC3, CXCL14, KCNH2) were consistently associated with nodal involvement and outcomes. Based on these genes, we developed the LION (Lymph-node Involvement Outcome Numerator) score, which distinguishes tumors with >pN1 disease and is associated with worse distant metastasis-free survival across cohorts. The LION score represents a biologically informed molecular metric associated with nodal involvement in ER+/HER2- BC. These findings provide insight into tumor-intrinsic epigenetic programs linked to dissemination.

  • Open Access

    Non-coding somatic single-nucleotide variations affecting glioblastoma-specific enhancer elements regulate tumor-promoting gene networks

    by Sandra Iñiguez-Muñoz, Pere Llinàs-Arias, Miquel Ensenyat-Mendez, Andrés F. Bedoya-López, Maria Solivellas-Pieras, Santiago Garfias-Arjona, Mónica Lara-Almúnia, Gabriel Matheu, Ananya Roy, Karin Forsberg-Nilsson, et al.

  • Open Access

    Epigenetic programs shaping lung metastasis in triple-negative breast cancer

    by Diego Marzese, Andres Bedoya-Lopez, Javier Orozco, Miquel Ensenyat-Mendez, Betsy Valdez, Sandra Iñiguez‑Muñoz, Alexander Boiko, Huiwen Xie, Maggie DiNome, Pere Llinàs-Arias

    Triple-negative breast cancer (TNBC) is a major cause of cancer mortality, with distant metastases presenting a significant clinical challenge. While epigenetic mechanisms like DNA methylation are known to influence TNBC progression, their specific role in driving metastasis remains underexplored. To address this gap, we performed comprehensive multi-omics analysis, integrating epigenomic and transcriptomic profiles from TNBC xenograft models and patient cohorts. Genome-wide DNA methylation profiling of primary tumors, lymph nodes, and lung metastases from xenografts revealed pronounced global hypomethylation in lung lesions, consistent with findings from the clinical cohort. Promoter-methylation changes were enriched in pathways linked to invasion and proliferation, and transcriptomic integration identified 22 epigenetically regulated genes. Among these, elevated AK1 , SLC2A5 , TPI1 , and ZBTB17 expression correlated with a higher risk of lung dissemination. These findings highlight altered DNA methylation as a driver of TNBC lung colonization and identify candidate prognostic markers, emphasizing the importance of epigenetic reprogramming in organ-specific lung metastases.


  • Open Access

    ASO Visual Abstract: Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen-Receptor-Positive, Clinically Node-Positive Disease

    by Miquel Ensenyat-Mendez, Dennis Rünger, Javier I. J. Orozco, Julie Le, Jennifer L. Baker, Joanne Weidhaas, Diego M. Marzese, Maggie L. DiNome

  • ASO Visual Abstract: Is the 21-Gene Recurrence Score on Core Needle Biopsy Equivalent to Surgical Specimen in Early-Stage Breast Cancer?

    by Javier I. J. Orozco, Shu-Ching Chang, Chikako Matsuba, Miquel Ensenyat-Mendez, Gary L. Grunkemeier, Diego M. Marzese, Janie G. Grumley


  • Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes

    by Maggie L. DiNome, Javier I. J. Orozco, Chikako Matsuba, Ayla O. Manughian-Peter, Miquel Ensenyat-Mendez, Shu-Ching Chang, John R. Jalas, Matthew P. Salomon, Diego M. Marzese

    Triple-negative breast cancer (TNBC) is a heterogeneous collection of breast tumors with numerous differences including morphological characteristics, genetic makeup, immune-cell infiltration, and response to systemic therapy. DNA methylation profiling is a robust tool to accurately identify disease-specific subtypes. We aimed to generate an epigenetic subclassification of TNBC tumors (epitypes) with utility for clinical decision-making. Genome-wide DNA methylation profiles from TNBC patients generated in the Cancer Genome Atlas project were used to build machine learning-based epigenetic classifiers. Clinical and demographic variables, as well as gene expression and gene mutation data from the same cohort, were integrated to further refine the TNBC epitypes. This analysis indicated the existence of four TNBC epitypes, named as Epi-CL-A, Epi-CL-B, Epi-CL-C, and Epi-CL-D. Patients with Epi-CL-B tumors showed significantly shorter disease-free survival and overall survival [log rank; P = 0.01; hazard ratio (HR) 3.89, 95% confidence interval (CI) 1.3-11.63 and P = 0.003; HR 5.29, 95% CI 1.55-18.18, respectively]. Significant gene expression and mutation differences among the TNBC epitypes suggested alternative pathway activation that could be used as ancillary therapeutic targets. These epigenetic subtypes showed complementarity with the recently described TNBC transcriptomic subtypes. TNBC epigenetic subtypes exhibit significant clinical and molecular differences. The links between genetic make-up, gene expression programs, and epigenetic subtypes open new avenues in the development of laboratory tests to more efficiently stratify TNBC patients, helping optimize tailored treatment approaches.